Overview
VCYT market data
Price History
VCYT price chart · 1M
- O
- 41.19
- H
- 41.19
- L
- 38.27
- C
- 38.52
- Vol
- 162,330.00
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $41.19
- Previous Close
- $40.14
- Day High
- $41.19
- Day Low
- $38.27
- 52 Week High
- $60.77
- 52 Week Low
- $38.27
- 7 Day Return
- -12.14%
- 30 Day Return
- -8.43%
- 90 Day Return
- -28.21%
- 1 Year Return
- -7.60%
- Daily Notional Volume
- $6.3M Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- 28.70 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $0.82 Diluted earnings per share over the trailing twelve months.
- Beta
- 2.03 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 20.4% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $29.46 – $60.91 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $3.3B · P/B 2.54 · P/S 5.85.
Company News
10 captured
Reasons to Retain Penumbra Stock in Your Portfolio for NowZacks Investment Research ·
Here's Why You Should Add BrightSpring Stock to Your Portfolio NowZacks Investment Research ·
Is This the Right Time to Retain Resmed Stock in Your Portfolio?Zacks Investment Research ·
8-K filing — VERACYTE, INC. (VCYT)SEC EDGAR ·
COO Q3 Earnings Top Estimates, Revenues Miss on Destocking, Stock DownZacks Investment Research ·
Reasons to Retain Tandem Diabetes Stock in Your Portfolio NowZacks Investment Research ·
GE HealthCare Moves StarGuide GX 4D SPECT/CT Toward FDA ClearanceZacks Investment Research ·
The Cooper Companies Gears Up to Post Q3 Earnings: What's in Store?Zacks Investment Research ·